TrialMed (New York, N.Y.)2022

Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults.

María Eugenia Toledo-Romani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.